Drug Type CAR-T |
Synonyms- |
Target |
Action antagonists |
Mechanism NKG2D antagonists(NKG2-D type II integral membrane protein antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Phase 1 | China | 01 Mar 2021 | |
Glioblastoma | Phase 1 | China | 01 Mar 2021 | |
Hepatocellular Carcinoma | Phase 1 | China | 01 Mar 2021 | |
Medulloblastoma | Phase 1 | China | 01 Mar 2021 | |
NKG2DL Positive Solid Tumors | Phase 1 | China | 01 Mar 2021 |